You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,125,862


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,125,862
Title:Porphyrin-metal complexes and oxygen infusions containing the same
Abstract: A porphyrin metal complex that can form a stable oxygen complex and acts effectively as an oxygen infusion, which comprises: a transition metal ion M of period 4 or 5 coordinating to a porphyrin derivative represented by the following general ##STR00001## wherein R.sup.1 is an alicyclic hydrocarbon group which may contain a substituent, R.sup.2 is an alkylene group and R.sup.3 is a group which does not hinder the coordination of an imidazolyl group to M.
Inventor(s): Tsuchida; Eishun (Tokyo, JP), Komatsu; Teruyuki (Tokyo, JP), Matsukawa; Yasuko (Tokyo, JP)
Assignee: Japan Science and Technology Agency (Saitama, JP)
Application Number:10/485,381
Patent Claims:1. A porphyrin metal complex comprising: a transition metal ion M of period 4 or 5 coordinating to a porphyrin derivative represented by the following general formula [I] ##STR00007## wherein R.sup.1 is an alicyclic hydrocarbon group selected from the group consisting of a 1-substituted cyclopropyl group, a 1-substituted cyclopentyl group, a 1-substituted cyclohexyl group, a 1-methyl-2-cyclohexenyl group, a 1-substiuted norbornyl group and a 1-substituted adamatyl group, R.sup.2 is an alkylene group and R.sup.3 is a group which does not hinder the coordination of an imidazolyl group to M.

2. A porphyrin metal complex represented by the following general formula [II]: ##STR00008## wherein M is a transition metal of period 4 or 5, R.sup.1 is an alicyclic hydrocarbon group selected from the group consisting of a 1-substituted cyclopropyl group, a 1-substituted evelopentyl group, a 1-substituted cyclohexyl group, a 1-methyl-2-cyclohexenyl group, a 1-substiuted norbomyl group and a 1-substituted adamatyl group, R.sup.2 is an alkylene group, R.sup.3 is a group that does not hinder the coordination of the imidazolyl group to M, X.sup.31 is a halogen ion and n denotes a number obtained by subtracting 2 from the valence number of M.

3. The porphyrin metal complex of claim 1, wherein R.sup.2 is a C.sub.2 to C.sub.10 alkylene group.

4. The porphyrin metal complex of claim 1, wherein R.sup.3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group.

5. The porphyrin metal complex of claim 1, wherein M is Fe or Co.

6. The porphyrin metal complex of claim 5, wherein M is Fe(II) or Fe(III).

7. The porphyrin metal complex of claim 5, wherein M is Co(II).

8. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 1.

9. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 1 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.

10. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 1 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.

11. The porphyrin metal complex of claim 2, wherein R.sup.2 is a C.sub.2 to C.sub.10 alkylene group.

12. The porphyrin metal complex of claim 2, wherein R.sup.3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group.

13. The porphyrin metal complex of claim 3, wherein R.sup.3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group.

14. The porphyrin metal complex of claim 2, wherein M is Fe or Co.

15. The porphyrin metal complex of claim 3, wherein M is Fe or Co.

16. The porphyrin metal complex of claim 4, wherein M is Fe or Co.

17. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 2.

18. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 3.

19. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 4.

20. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 5.

21. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 6.

22. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 7.

23. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 2 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.

24. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 3 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.

25. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 4 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.

26. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 5 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.

27. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 6 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.

28. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 7 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.

29. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 2 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.

30. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 3 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.

31. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 4 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.

32. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 5 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.

33. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 6 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.

34. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 7 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.

Details for Patent 7,125,862

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2021-07-30
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2021-07-30
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2021-07-30
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 08/15/1978 ⤷  Try a Trial 2021-07-30
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 02/17/1995 ⤷  Try a Trial 2021-07-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.